BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Big Cap Pro

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years $2276.64 only $796.82

ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,969.34
      0.35%
      US Tech 100
      20,266.40
      0.33%
      Dow Jones
      44,296.51
      0.97%
      Brent Oil
      74.745
      -0.03%
      Bitcoin
      98,186.00
      0.32%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Stoke Therapeutics Inc (STOK) Quote

      Stoke Therapeutics Inc

      Stoke Therapeutics Inc (STOK)

      NASDAQ
      11.43
      0.16
      (1.42%)
      Closed November 25 4:00PM
      Delayed by 15 minutes
      11.43
      -0.01
      (-0.09%)
      After Hours: 5:16PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      11.43
      Bid
      10.00
      Ask
      13.17
      Volume
      243,374
      11.15 Day's Range 11.60
      3.77 52 Week Range 17.58
      Market Cap
      605.413M
      Previous Close
      11.27
      Open
      11.32
      Last Trade
      129
      @
      11.43
      (priorref)
      Last Trade Time
      Financial Volume
      $ 2,773,778
      VWAP
      11.3972
      Average Volume (3m)
      577,536
      Shares Outstanding
      52,966,977
      Dividend Yield
      -
      PE Ratio
      -5.79
      Earnings Per Share (EPS)
      -1.98
      Revenue
      8.78M
      Net Profit
      -104.7M

      About Stoke Therapeutics Inc

      Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively... Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.stoketherapeutics.com
      Headquarters
      Dover, Delaware, USA
      Founded
      -
      Stoke Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker STOK. The last closing price for Stoke Therapeutics was $11.27. Over the last year, Stoke Therapeutics shares have traded in a share price range of $ 3.77 to $ 17.58.

      Stoke Therapeutics currently has 52,966,977 shares outstanding. The market capitalization of Stoke Therapeutics is $596.94 million. Stoke Therapeutics has a price to earnings ratio (PE ratio) of -5.79.

      Ask ADVFN Intelligence (AI)

      STOK Latest News

      More News

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 14 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      November 05 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 05 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 05 2024
      Edgar (US Regulatory)

      Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

      – Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing in studies of zorevunersen by...

      November 05 2024
      Business Wire

      Form 144 - Report of proposed sale of securities

      November 01 2024
      Edgar (US Regulatory)

      Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

      October 09 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      October 02 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      September 23 2024
      Edgar (US Regulatory)

      Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

      September 23 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-2.45-17.6512968313.8813.9511.0862015911.77669135CS
      4-0.62-5.1452282157712.0514.7211.0847057412.72636435CS
      12-2.56-18.298784846313.9916.1511.0857753613.27278366CS
      26-3.91-25.488917861815.3417.5811.0858666913.94523064CS
      527.51191.5816326533.9217.583.7769192812.20394904CS
      156-17.87-60.989761092229.333.06353.3542932712.21637641CS
      260-11.45-50.043706293722.8871.583.3531906316.39998724CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      PDYNPalladyne AI Corporation
      $ 4.59
      (129.50%)
      		83M
      QMCOQuantum Corporation
      $ 9.11
      (126.62%)
      		39.41M
      NANano Labs Ltd
      $ 8.26
      (89.02%)
      		2.03M
      XCURExicure Inc
      $ 18.60
      (71.27%)
      		4.36M
      SKKSKK Holdings Limited
      $ 1.75
      (59.09%)
      		95.06M
      AMIXAutonomix Medical Inc
      $ 6.21
      (-54.07%)
      		946.09k
      CETXCemtrex Inc
      $ 0.1146
      (-41.74%)
      		24.39M
      MSWMing Shing Group Holdings Ltd
       5.90
      (-35.52%)
      		417.08k
      RMSGReal Messenger Corporation
      $ 3.09
      (-26.25%)
      		313.51k
      ENSCEnsysce Biosciences Inc
      $ 0.4414
      (-25.49%)
      		4M
      ELABElevai Labs Inc
      $ 0.0201
      (-0.50%)
      		415.87M
      NVDANVIDIA Corporation
      $ 141.95
      (-3.22%)
      		229.93M
      SMCISuper Micro Computer Inc
      $ 33.15
      (11.62%)
      		155.43M
      VRPXVirpax Pharmaceuticals Inc
      $ 0.5501
      (-6.72%)
      		154.17M
      SOUNSoundHound AI Inc
      $ 8.24
      (18.05%)
      		103.6M

      STOK Discussion

      View Posts
      Monksdream Monksdream 3 months ago
      FOLD under $15
      👍️0
      Zardiw Zardiw 8 months ago
      $STOK Chart from #DDAmanda - #1 Stock Screener :

      Scans are preset. Push a Button. Find Winners Early:



      Z
      👍️0
      TimeFades TimeFades 8 months ago
      Choppy day shoulda just stuck with my morning short
      👍️0
      TimeFades TimeFades 8 months ago
      Got bullish again and covered
      👍️0
      TimeFades TimeFades 8 months ago
      Short from 12s
      👍️0
      Invest-in-America Invest-in-America 8 months ago
      STOK: "Stoke Therapeutics (NASDAQ:STOK) stock shot up 70% in post-market trading Monday after the company reported positive results from studies for its drug STK-001 in the treatment of children and adolescents with Dravet syndrome, a genetic form of epilepsy. The biotech company said data from two Phase 1/2a studies and two open label extension, or OLE, studies showed “clinically meaningful effects” that included “substantial and durable reductions in convulsive seizure frequency."
      https://seekingalpha.com/news/4083468-stoke-stock-soars-post-market-on-epilepsy-drug-data

      Dravet Syndrome is an extremely RARE disease in the USA. And the above news does NOT specify nor suggest that STOK's (potential) treatment for Dravet Syndrome will or might have any applications for treatment of EPILEPSY at all. (Be very CAREFUL about news like the above.)
      👍️0

      Your Recent History

      NASDAQ
      STOK
      Stoke Therapeutics
      NASDAQ
      WTMAU
      Welsbach Technology Meta...
      LSE
      90SY
      Assa 27
      ASX
      LIC
      Lifestyle Communities
      Delayed Upgrade Clock